Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 19;76(2):533-535.
doi: 10.1093/jac/dkaa450.

Distinct evolution of colistin resistance associated with experimental resistance evolution models in Klebsiella pneumoniae

L B S Aulin  1 , C I M Koumans  1 , Y Haakman  1 , W van Os  1 , M E M Kraakman  2 , J Gooskens  2 , W K Smits  2 , A Liakopoulos  3 , J G C van Hasselt  1
Affiliations

Distinct evolution of colistin resistance associated with experimental resistance evolution models in Klebsiella pneumoniae

L B S Aulin et al. J Antimicrob Chemother. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Overview of experimental in vitro models for evolution of antibiotic resistance. (b) SNPs identified in mutants evolved from two parental clinical isolates of Klebsiella pneumoniae, KML9884 and KML9749, in three different in vitro experiments in which the bacteria were treated with colistin over 48 h. Mutated genes are shown as panels with the specific nucleotide substitution followed by the amino acid substitution on the x-axis. Deletions, duplications and frameshift mutations are denoted del, dup and fs, respectively. Colour indicates colistin MIC values (mg/L) and the enclosed numbers represents replicate identity. The MICs of both parental strains were ≤1 mg/L. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
See this image and copyright information in PMC

References

    1. WHO. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. 2017. https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-E....
    1. Petrosillo N, Giannella M, Lewis R. et al. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther 2013; 11: 159–77. - PubMed
    1. Poirel L, Jayol A, Nordmann P.. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev 2017; 30: 557–96. - PMC - PubMed
    1. Karaiskos I, Friberg LE, Pontikis K. et al. Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients. Antimicrob Agents Chemother 2015; 59: 7240–8. - PMC - PubMed
    1. Food and Drug Administration. Coly-Mycin M Parenteral (colistimethate for injection, USP) NDA 50-108/S-026 https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050108s026lbl.pdf.

Publication types

MeSH terms